Restrictive Lung Disease Flashcards
Functions of type II pneumocytes
Synthesis of surfactant, alveolar epithelial repair, and ion and fluid transport
Microatelectasis
Collapse of alveoli on a microscopic level
Four surfactant-associated proteins
SP-A, SP-B, SP-C, SP-D
SP-A and SP-D are opsonins that function in lung defense.
SP-B and SP-C are particularly crucial for surfactant function.
When type I cells are damaged, the reparative process involves . . .
. . . hyperplasia of the type II cells and eventual differentiation into type I-like cells.
Normally, this results in some hyperplastic type II cells undergoing apoptosis, while the remainder transdifferentiate into thin, delicate, type I cells. If this process is defective, it may instead result in idiopathic pulmonary fibrosis.
Unlike the alveolar epithelial cells, which are ____, junctions between capillary endothelial cells permit ____.
Unlike the alveolar epithelial cells, which are quite impermeable under normal circumstances, junctions between capillary endothelial cells permit passage of small-molecular-weight proteins.
Major components of lung insterstitial spaces
Collagen, elastin, proteoglycans, a variety of macromolecules involved with cell-cell and cell-matrix interactions, some nerve endings, and some fibroblast-like cells. Also some lymphocytes.
‘Insterstitial’ in interstitial lung disease
The interstitium formally refers only to the region of the alveolar wall exclusive of and separating the alveolar epithelial and capillary endothelial cells.
However, interstitial lung diseases affect all components of the alveolar wall: epithelial cells, endothelial cells, and cellular and noncellular components of the interstitium. In addition, the disease process often extends into the alveolar spaces and therefore is not limited to the alveolar wall.
The idiopathic interstitial pneumonias represent . . .
The idiopathic interstitial pneumonias represent a subgroup of disorders within the broader category of diffuse parenchymal lung disease/interstitial lung disease.
Two components of most diffuse parenchymal lung diseases
- Inflammatory
- Fibrotic
Hypersensitivity pneumonitis
Granulomatous inflammation induced by hypersensitivity against a particular substance. Common cause of lung granulomas, along with sarcoidosis.
Many potential agents have been identified (including possibly vitamin E acetate)
Idiopathic interstitial pneumonias
Display variable amounts of nonspecific inflammation and fibrosis, and they lack granulomas or specific pathologic features characteristic of other previously well-defined diseases. Sometimes come along with a rheumatic disease, like scleroderma.
Almost any diffuse parenchymal lung disease, given enough time, will . . .
. . . lose any distinctive features of prior interstitial inflammation or alveolitis and just look like extensive fibrosis, sometimes with cysts. Even granulomas will disappear.
Thus, we say they all converge at end-stage diffuse parenchymal lung disease
Genes that predispose to diffuse parenchymal lung disease
- MUC5B
- hTERT
- SP-C
Loss of MUC5B would remove the lung’s shield to particulate damage, loss of hTERT makes it less possible to regenerate tissue, and loss of SP-C makes surfactant dysfunctional.
Pathogenetic features of diffuse parenchymal lung disease
- Initiation (by antigens or toxins)
- Propagation (through the inflammatory response)
- Fibrosis
Functional consequences of fibrosis
- Decreased compliance
- Decrease in lung volumes
- Loss of alveolar-capillary surface area and impaired diffusing capacity
- Isolated abnormalities in small airway function
- Disturbances in gas exchange (usually hypoxemia w/o CO2 retention)
- Pulmonary hypertension
Patients with diffuse parenchymal lung disease tend to breathe . . .
Patients with diffuse parenchymal lung disease tend to breathe with smaller tidal volumes but increased respiratory frequency
Decreases in TLC, FRC, and RV in restrictive lung diseases are . . .
Decreases in TLC, FRC, and RV in restrictive lung diseases are direct consequences of the change in lung compliance.
Mechanism of reduced diffusing capacity in diffuse parenchymal lung disease
It’s actually NOT membrane thickening, which most people expect.
Rather, the processes of inflammation and fibrosis destroy a portion of the alveolar-capillary interface and reduce the surface area available for gas exchange. You have less functional alveolar space per alveolus.
Abnormalities in Small Airways Function in diffuse parenchymal lung disease
Large airways usually function normally, and so FEV1/FVC is usually normal or even increased.
However, inflammation and fibrosis in the peribronchiolar regions often narrow the lumen of the small airways or bronchioles, increaseing resistance to flow in these smaller channels (detectable on FEF25%-75%)
Mechanism of hypoxia in restrictive lung disease
Hypoxemia without CO2 retention, and in fact hypocapnia typically is present.
V̇/Q̇ mismatch is major contributor.
Pulmonary hypertension is common in severe diffuse parenchymal lung disease, resulting from ___
Pulmonary hypertension is common in severe diffuse parenchymal lung disease, resulting from hypoxemia and obliteration of small pulmonary vessels.
Patients with diffuse parenchymal lung disease most commonly have ___ as the presenting symptom
Patients with diffuse parenchymal lung disease most commonly have dyspnea as the presenting symptom
Clinical features of diffuse parenchymal lung disease
- Dyspnea
- Cough, usually nonproductive
- Dry inspiratory crackles on auscultation, most prominent at lung bases
Radiographic picture of diffuse parenchymal involvement
Interstitial pattern, with enhanced lung-markings
Possible retracted lungs due to changed FRC and TLC.
Diagnostic distinction between the different types of diffuse parenchymal lung disease often requires ___.
Diagnostic distinction between the different types of diffuse parenchymal lung disease often requires investigation at the microscopic or histologic level (biopsy or bronchoalveolar lavage)
___ is rarely a feature of diffuse parenchymal lung disease, and if it appears is often indicative of a complicating process (like infection)
Hypercapnia is rarely a feature of diffuse parenchymal lung disease, and if it appears is often indicative of a complicating process (like infection)
Conceptual framework for idiopathic pulmonary fibrosis
- Injury to alveolar epithelial cells by unknown agent
- Defective type II pneumocyte hyperplasia and differentiation response
- PDGF/TGFb-driven fibroblast activation
- Fibrosis
TERC gene
Telomerase RNA component
The RNA transcript that telomerase uses as a guide RNA! Disruption of this gene can, of course, lead to telomere mismanagement
Clinical picture for idiopathic pulmonary fibrosis
- 50-70 yr old on first presentation
- Insidious onset
- Dyspnea chief compaint
- Dry crackles on examination
- Clubbing of digits
- Interstitial pattern on CXR
- Honeycombing on CT
- ANA test
Honeycomb CT scan
Typical for idiopathic pulmonary fibrosis. Indicative of extensive, irreversible lung fibrosis.
Treatments for idiopathic pulmonary fibrosis
Nintedanib - tyrosine kinase inhibitor that blocks downstream signaling of several fibrogenic growth factors, including PDGF, FGF, and VEGF
Anti-TGFb
Lung transplant